# Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin

> **NCT00563732** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Lecozotan

## Key facts

- **NCT ID:** NCT00563732
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** — (—)
- **Last updated:** 2008-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563732, "Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00563732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*